<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00083096</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-16027-26023</org_study_id>
    <secondary_id>EORTC-16027</secondary_id>
    <secondary_id>EORTC-26023</secondary_id>
    <secondary_id>SPRI-P03174</secondary_id>
    <nct_id>NCT00083096</nct_id>
  </id_info>
  <brief_title>Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas</brief_title>
  <official_title>Phase I Study Of SCH66336 (Lonafarnib), A Farnesyl Protein Transferase Inhibitor In Combination With Temozolomide In Gliomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Lonafarnib may stop the growth of tumor cells by blocking the enzymes necessary&#xD;
      for their growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to&#xD;
      stop tumor cells from dividing so they stop growing or die. Giving lonafarnib together with&#xD;
      temozolomide may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of lonafarnib when&#xD;
      given together with temozolomide in treating patients with recurrent primary supratentorial&#xD;
      glioma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose and dose-limiting toxicity of lonafarnib when&#xD;
           administered with temozolomide in patients with recurrent primary supratentorial&#xD;
           gliomas.&#xD;
&#xD;
        -  Determine the safety and tolerability of this regimen in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the mechanism of action of lonafarnib in these patients.&#xD;
&#xD;
        -  Determine the pharmacodynamics and pharmacokinetics of this regimen in these patients.&#xD;
&#xD;
        -  Determine the activity of this regimen in these patients.&#xD;
&#xD;
        -  Determine the response to this regimen in patients who have measurable disease.&#xD;
&#xD;
      OUTLINE: This is a nonrandomized, multicenter, open-label, dose-escalation study of&#xD;
      lonafarnib.&#xD;
&#xD;
      Patients receive oral temozolomide once daily on days 2-6 of course 1 and on days 1-5 of all&#xD;
      subsequent courses. Patients also receive oral lonafarnib twice daily on days 1-28. Courses&#xD;
      repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of lonafarnib until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose at which 1 of 6 patients experience&#xD;
      dose-limiting toxicity. An additional 3 patients may be treated at the highest dose level&#xD;
      achieved.&#xD;
&#xD;
      Patients are followed every 8 weeks for 6 months and then every 3 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 3-30 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2004</start_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity and maximum tolerated dose of lonafarnib determined by CTCAE v3.0</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response (complete [CR] or partial response [PR]) measured by McDonald's criteria at least 4 weeks after first documented response and every 8 weeks until disease progression or until start of another treatment</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lonafarnib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed primary supratentorial glioma&#xD;
&#xD;
               -  Multifocal disease allowed&#xD;
&#xD;
          -  Recurrent disease after prior surgery and/or radiotherapy&#xD;
&#xD;
          -  Radiological evidence of increased and/or enhanced target lesion&#xD;
&#xD;
          -  Amenable to temozolomide therapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2 OR&#xD;
&#xD;
          -  WHO 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 10.0 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Alkaline phosphatase &lt; 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Transaminases &lt; 2.5 times ULN&#xD;
&#xD;
          -  Bilirubin &lt; 1.5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine &lt; 1.7 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  Cardiac function clinically normal&#xD;
&#xD;
          -  Normal 12-lead ECG&#xD;
&#xD;
          -  QTc ≤ 440 msec on ECG&#xD;
&#xD;
          -  No ischemic heart disease within the past 6 months&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after study&#xD;
             participation&#xD;
&#xD;
          -  No unstable systemic disease&#xD;
&#xD;
          -  No active uncontrolled infection&#xD;
&#xD;
          -  No psychological, familial, sociological, or geographical condition that would&#xD;
             preclude study compliance and follow-up&#xD;
&#xD;
          -  No other active or recurrent malignancy within the past 5 years except cone biopsied&#xD;
             carcinoma of the cervix or adequately treated basal cell or squamous cell skin cancer&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent anticancer biologic agents&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for temozolomide)&#xD;
&#xD;
          -  Prior adjuvant chemotherapy allowed&#xD;
&#xD;
          -  No more than 1 prior chemotherapy regimen for recurrent disease&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Concurrent corticosteroids allowed provided treatment remains at a stable or&#xD;
             decreasing dose for at least 2 weeks&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 months since prior surgery for primary brain tumor&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Concurrent anticonvulsants allowed&#xD;
&#xD;
          -  No other concurrent anticancer agents&#xD;
&#xD;
          -  No other concurrent investigational therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mario Campone, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Regional Rene Gauducheau</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre de Lutte Contre le Cancer Georges-Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional Rene Gauducheau</name>
      <address>
        <city>Nantes-Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>May 14, 2004</study_first_submitted>
  <study_first_submitted_qc>May 14, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2004</study_first_posted>
  <last_update_submitted>February 9, 2015</last_update_submitted>
  <last_update_submitted_qc>February 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>adult mixed glioma</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult anaplastic oligodendroglioma</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult pilocytic astrocytoma</keyword>
  <keyword>adult anaplastic ependymoma</keyword>
  <keyword>adult subependymoma</keyword>
  <keyword>adult myxopapillary ependymoma</keyword>
  <keyword>adult oligodendroglioma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <keyword>adult diffuse astrocytoma</keyword>
  <keyword>adult subependymal giant cell astrocytoma</keyword>
  <keyword>adult pineal gland astrocytoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Lonafarnib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

